USPTO serial 79380667
S SENSIBLE BIOTECHNOLOGIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 28, 2026
- Examiner
- FENNESSY, EDWARD JOHN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with S SENSIBLE BIOTECHNOLOGIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Marek Krizka
Marek Krizka TRAMA LEGAL, PLLC1178 Broadway, Fl 3New York, NY 10001United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for use in industry; cell culture media for use in the biotechnological industry for scientific and research use; cell culture reagents for scientific and research use; biological preparation for use in cell cultures other than for medical or veterinary use; chemical for use in biotechnological manufacturing processes for use in molecular separation processes other than for medical or veterinary use; chemical for use in biotechnological product development for use in molecular separation processes other than for medical or veterinary use; cultures of microbiotic organisms, other than for medical use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; cell culture media for microbiology for scientific and research purposes; biological preparations for use in science; biological preparations for use in industry; biological preparations for use in cell cultures, other than for medical or veterinary purposes | ACTIVE | — |
| 005 | Biotechnological preparations for use in cell cultures for medical purposes; cells for medical use; living cells for medical use | ACTIVE | — |
| 035 | Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies | ACTIVE | — |
| 042 | Biotechnology testing of pharmaceutical preparations for gene therapy, pharmaceuticals, chemicals and cell culture media; consulting services in the field of biotechnology; research and development in the pharmaceutical and biotechnology fields; writing of computer programs for biotechnological applications; development of measuring probes for biotechnological applications; research and development of new products in the field of biotechnology; designing equipment for the biotechnology industry; providing information on the subject of scientific research in the field of biochemistry and biotechnology; research in the field of cell engineering technology; cell culture services for scientific and research purposes, for others; analysis in the field of molecular biology, namely, messenger RNA analysis to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies; research relating to molecular sciences; contract research services relating to molecular sciences; microbiological testing of cell culture media, DNA and RNA to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies medical research; pharmaceutical research; biochemical analyses; biochemical research and development services in the field of messenger RNA to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies; laboratory analyses of materials, namely, DNA and RNA materials to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies; biochemical research; biochemical analysis; biochemical research and development; biological laboratory research; chemical laboratory research; laboratory testing of materials; laboratory research in the field of chemistry; DNA testing for scientific research purposes, namely, DNA screening, determining DNA mutations; chemical laboratory services; biological research laboratory services; genetic engineering services in the field of genetic diseases; chemical analysis; scientific research in the field of genetics and genetic engineering; research and development in the field of microorganisms and cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sensible Biotechnologies s. r. o.
- Other trademarks owned by Sensible Biotechnologies s. r. o.
- Other trademarks owned by Sensible Biotechnologies s. r. o.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named S SENSIBLE BIOTECHNOLOGIES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 22, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 1, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 30, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 28, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 28, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 28, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 12, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 12, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 12, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 10, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 10, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 10, 2026 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jan 24, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 24, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 24, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 7, 2025 | RDX3 | NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED | — |
| Jul 7, 2025 | RDX1 | ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED | — |
| Jul 7, 2025 | RRDX | ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED | — |
| Apr 23, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 23, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 23, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 4, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 29, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 11, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 11, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 23, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 23, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 23, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 11, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 11, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 11, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 10, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 10, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 10, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 8, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 19, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 18, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 25, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 24, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 23, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 24, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 18, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 12, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |